Form 4: RVP CEO Thomas Shaw Buys Shares

Retractable Technologies CEO Thomas Shaw purchased 2,100 shares of common stock at $0.8118 per share, increasing his direct beneficial ownership.

Summary

• Thomas J. Shaw, President and CEO, Director, and 10% Owner of Retractable Technologies Inc. (RVP), acquired 2,100 shares of common stock.
• The transaction occurred on August 11, 2025, at a weighted average price of $0.8118 per share.
• This purchase was executed under a Rule 10b5-1 plan adopted on August 22, 2024.
• Following this transaction, Mr. Shaw directly beneficially owns 15,580,854 shares of common stock.
• He also indirectly beneficially owns 831,600 shares, with investment power over 500,000 shares as a Trustee for a family member and voting control over the remainder via a voting agreement.

Sentiment

Score: 7

Explanation: The insider purchase by the CEO is a positive signal of confidence, especially given his significant existing stake. However, the relatively small size of the purchase limits its overall impact on sentiment.

Positives

• Insider buying by the President and CEO, Director, and 10% Owner, Thomas J. Shaw, signals confidence in the company's future prospects.
• The purchase was made under a pre-arranged Rule 10b5-1 plan, indicating a planned investment strategy rather than a reaction to immediate market events.

Negatives

• The number of shares purchased (2,100) is relatively small compared to Mr. Shaw's existing substantial holdings (over 15 million direct shares), suggesting a minor incremental investment rather than a significant new commitment.

Future Outlook

NA

Industry Context

Insider purchases, especially by top executives like the CEO, are generally viewed positively by the market as they indicate management's belief in the company's intrinsic value and future performance. In the medical device industry, such a purchase could signal confidence in upcoming product developments, market expansion, or favorable regulatory outcomes, though the specific filing does not provide these details.

Comparison to Industry Standards

• While the purchase of 2,100 shares is a positive signal, its relatively small size compared to the CEO's existing holdings means it is not a significant capital allocation event.
• For comparison, larger insider purchases by executives in similar-sized medical device companies, such as a CEO buying hundreds of thousands or millions of dollars worth of shares, would typically generate more substantial market interest and signal a stronger conviction.
• This transaction is more indicative of routine, planned accumulation rather than a major strategic move.

Related Party Transactions

• Thomas J. Shaw indirectly beneficially owns 831,600 shares, including 500,000 shares over which he has investment power as Trustee for the benefit of a family member, and voting control over the remainder via a voting agreement.

Stakeholder Impact

• Shareholders may view the CEO's purchase as a positive sign of management confidence in the company's future, potentially bolstering investor sentiment.
• Employees and other stakeholders might interpret the insider buying as a stable outlook for the company.

Key Dates

Recommendation

While the CEO's purchase of shares is a positive indicator of insider confidence, the relatively small volume of shares acquired (2,100) compared to his substantial existing holdings suggests it's not a major new investment. The transaction was also pre-planned under a Rule 10b5-1 plan, which reduces its immediate signaling power compared to an open-market, discretionary purchase. Given these factors, the filing reinforces a 'hold' position, indicating no strong reason to buy or sell based solely on this specific transaction, but rather to maintain existing positions while awaiting more significant operational or financial news.

Keywords

Retractable Technologies, RVP, Insider Trading, Form 4, Thomas J. Shaw, CEO Stock Purchase, Rule 10b5-1 Plan, Medical Devices, Healthcare